-

PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global commercial biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025 at 1:45 pm. PST.

A live webcast of management's remarks will be available through the News section of PharmaEssentia’s website at https://us.pharmaessentia.com/news/. Replays of the webcast will be archived on the Company's website for at least 30 days.

About PharmaEssentia
PharmaEssentia (TWSE: 6446), headquartered in Taipei, Taiwan, is a commercial-stage, global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversified pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

For more information about PharmaEssentia USA, visit our website, LinkedIn or X.

© 2024 PharmaEssentia Corporation. All rights reserved.

Contacts

Investor and Media
Muriel Huang, muriel_huang@pharmaessentia.com

Industry:

PharmaEssentia Corporation

TSE:6446
Details
Headquarters: Taipei, Taiwan
CEO: Ko-Chung Lin
Employees: 600
Organization: PUB
Release Versions
English

Contacts

Investor and Media
Muriel Huang, muriel_huang@pharmaessentia.com

More News From PharmaEssentia Corporation

PharmaEssentia Announces Health Canada Approval of BESREMi® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that its wholly owned subsidiary, FORUS Therapeutics Inc, has received a Notice of Compliance (NOC) authorizing BESREMi® (ropeginterferon alfa-2b) for the treatment of adults with polycythemia vera (PV). BESREMi® is expected to become commer...

PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the U.S. Food and Drug Administration (FDA) approval and launch of the BESREMi Pen™ (ropeginterferon alfa-2b-njft) device for adult patients with polycythemia vera (PV). The device offers a mor...

PharmaEssentia Expands North American Commercial Footprint with Acquisition of Canadian Partner FORUS Therapeutics

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan, today announced the acquisition of FORUS Therapeutics Inc. ("FORUS"), a Canadian specialty pharmaceutical company, in a transaction valued at US$36.5 million. The acquisition represents an important component of PharmaEssentia's North American commercial strategy and marks a significant milestone in the company's global expansion. PharmaEssentia entered into a...
Back to Newsroom